Abstract 4720
Background
ABBV-428 is a bispecific antibody designed for MSLN-dependent CD40 activation. Preliminary results of a phase I first-in-human, dose-escalation (DE)/dose-expansion study of ABBV-428 in pts with advanced solid tumors including pts who express MSLN at high levels are reported (NCT02955251).
Methods
Pts received ABBV-428 in a 3 + 3 DE design: 0.01–3.6 mg/kg IV doses every 2 weeks. Response was assessed per RECIST v1.1. Serial PK and biomarker samples were collected. Primary objectives were to evaluate ABBV-428 monotherapy safety, PK, and preliminary efficacy.
Results
As of 28 Feb 2019, 59 pts were enrolled in DE (≤0.4 mg/kg, n = 21; 0.8–2.4 mg/kg, n = 10; 3.6 mg/kg, n = 28). Median prior treatment (Tx): 3 (range 1.0–11.0); median Tx duration: 6.1 weeks (range 0.1–73.1). PK exhibited a dose-proportional increase with half-life value 10–17 hours (0.4–3.6 mg/kg); no accumulation was observed between cycles 1–3. Antidrug antibodies were detected across all dose levels in 64% of pts, with impact on exposure observed at dose levels <0.8 mg/kg. No DLTs occurred. Expansion dose: 3.6 mg/kg; >90% receptor occupancy did not result in serious/high-grade liver function test abnormalities or cytokine release syndrome. Transient B-cell depletion and upregulation of B-cell activation markers was observed in peripheral blood (all dose groups). Overall, 56 (94.9%) pts reported ≥1 Tx-emergent adverse event (TEAE); 36 pts reported grade ≥3 TEAE, 3 possibly related to ABBV-428. TEAEs leading to death (n = 14) were not related to ABBV-428. Of the 50 evaluable pts, none had an objective response (confirmed partial or complete response), 25 (50.0%) had stable disease (SD), and 25 (50.0%) had progressive disease. Tx is ongoing in 3 pts (all SD > 6 months).
Conclusions
Targeting the tumor microenvironment with ABBV-428 was successful in achieving immune agonism without systemic toxicity in MSLN-expressing advanced solid tumors; however, no significant clinical benefit was observed. Potential mechanisms and additional biomarker/translational findings related to these observations will be presented.
Clinical trial identification
NCT02955251.
Editorial acknowledgement
Mary L. Smith, PhD, CMPP, from Aptitude Health, Atlanta, GA, funded by AbbVie.
Legal entity responsible for the study
AbbVie Inc.
Funding
AbbVie Inc.
Disclosure
J.J. Luke: Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Array BioPharma; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: EMD Serono; Advisory / Consultancy, Travel / Accommodation / Expenses: BeneVir; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Checkmate Pharmaceuticals; Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca/MedImmune; Advisory / Consultancy: 7 Hills Pharma; Advisory / Consultancy, Travel / Accommodation / Expenses: Castle Biosciences; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Actym Therapeutics; Advisory / Consultancy, Travel / Accommodation / Expenses: Gilead Sciences; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: NewLink Genetics; Advisory / Consultancy, Travel / Accommodation / Expenses: RefleXion Medical; Advisory / Consultancy: Syndax; Advisory / Consultancy: Tempest Therapeutics; Advisory / Consultancy: TTC Oncology; Advisory / Consultancy: Alphamab; Advisory / Consultancy: Mavupharma; Advisory / Consultancy: Aduro Biotech; Advisory / Consultancy, Research grant / Funding (institution): Compugen; Advisory / Consultancy, Travel / Accommodation / Expenses: IDEAYA Biosciences; Advisory / Consultancy: Spring Bank; Advisory / Consultancy: WntRx Pharmaceuticals; Advisory / Consultancy: Jounce Therapeutics; Advisory / Consultancy: Vividion Therapeutics; Licensing / Royalties, Cancer Immunotherapy: Serial #15/612,657 ; Licensing / Royalties, Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Serial #PCT/US18/36052 ; Research grant / Funding (institution): Boston Biomedical; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Celldex; Research grant / Funding (institution): Incyte; Research grant / Funding (self): Genentech/Roche; Research grant / Funding (institution): Pharmacyclics; Research grant / Funding (institution): Five Prime Therapeutics; Research grant / Funding (institution): Corvus Pharmaceuticals; Research grant / Funding (institution): Delcath Systems; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Immunocore; Research grant / Funding (institution): MacroGenics; Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): Xencor; Research grant / Funding (institution): Evelo Therapeutics; Research grant / Funding (institution): Palleon Pharmaceuticals; Research grant / Funding (institution): FLX Bio. L. Fong: Advisory / Consultancy: Atreca; Advisory / Consultancy: BioAtla; Advisory / Consultancy: Bolt; Advisory / Consultancy: IDEAYA; Advisory / Consultancy: Nutcracker; Advisory / Consultancy: Senti; Advisory / Consultancy: TeneoBio; Research grant / Funding (institution): AbbVie ; Research grant / Funding (institution): Bavarian Nordic ; Research grant / Funding (institution): Bristol-Myers Squibb ; Research grant / Funding (institution): Dendreon ; Research grant / Funding (institution): Janssen Oncology ; Research grant / Funding (institution): Merck ; Research grant / Funding (institution): OncoSec ; Research grant / Funding (institution): Roche/Genentech . K. Chung: Speaker Bureau / Expert testimony: Genentech. A.W. Tolcher: Shareholder / Stockholder / Stock options, Ownership: NEXT Oncology; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: AbbVie; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: ADC Therapeutics; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Adagene; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Agenus; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Aro Biotherapeutics; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Ascentage; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: AxImmune; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Bayer; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: BioInvent; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Birdie; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Boston Bio; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: EMD Serono; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Forbius; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: HBM Partners; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Ignyta; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Immunome; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Immunomet; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Jazz; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Mekanistic; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Nanobiotix; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: NBE Therapeutics; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Nuvalent; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Deciphera; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Pelican; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Pierre Fabre; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Ridgeway; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Scitemex; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Sesen; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Seattle Genetics; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Symphogen; Advisory / Consultancy, Travel / Accommodation / Expenses, Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Syneos; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Aminex; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Asana; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Arrys; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: CStone; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: GlaxoSmithKline; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: InhibRx; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Innate ; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Kiromie; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Mersana; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: NatureWise; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: NextCure; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Nitto Biopharma; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Pieris; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Syndax; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Tizona; Research grant / Funding (institution), Payments for Advisory/Consultancy/Research funding are paid to NEXT Oncology: Zymeworks. K. Kelly: Honoraria (self), Travel / Accommodation / Expenses: Merck; Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Advisory / Consultancy, Travel / Accommodation / Expenses: ARIAD; Advisory / Consultancy, Travel / Accommodation / Expenses, Licensing / Royalties: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: G1 Therapeutics; Advisory / Consultancy, Travel / Accommodation / Expenses: Genentech/Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Regeneron; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): EMD Serono; Research grant / Funding (institution): Five Prime Therapeutics; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Lycera; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Transgene; Licensing / Royalties, evidence-based, peer-reviewed information resource: Author Royalties for UpToDate. A. Hollebecque: Advisory / Consultancy, Travel / Accommodation / Expenses, Non-remunerated activity/ies: Amgen; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca/MedImmune; Advisory / Consultancy: Gritstone Oncology; Advisory / Consultancy: Incyte; Advisory / Consultancy, Travel / Accommodation / Expenses, Non-remunerated activity/ies: Lilly; Advisory / Consultancy: Spectrum Pharmaceuticals; Travel / Accommodation / Expenses, Non-remunerated activity/ies: SERVIER; Non-remunerated activity/ies: AbbVie; Non-remunerated activity/ies: Agios; Non-remunerated activity/ies: Argenx; Non-remunerated activity/ies: Arno Therapeutics; Non-remunerated activity/ies: Astex Pharmaceuticals; Non-remunerated activity/ies: AstraZeneca; Non-remunerated activity/ies: AVEO; Non-remunerated activity/ies: Bayer; Non-remunerated activity/ies: Blueprint Medicines; Non-remunerated activity/ies: Boehringer Ingelheim; Non-remunerated activity/ies: Bristol-Myers Squibb; Non-remunerated activity/ies: Celgene; Non-remunerated activity/ies: Chugai Pharma; Non-remunerated activity/ies: Clovis Oncology; Non-remunerated activity/ies: Daiichi Sankyo; Non-remunerated activity/ies: Debiopharm; Non-remunerated activity/ies: Group; Non-remunerated activity/ies: Eisai; Non-remunerated activity/ies: Exelixis; Non-remunerated activity/ies: GamaMabs Pharma; Non-remunerated activity/ies: Forma Therapeutics; Non-remunerated activity/ies: Genentech; Non-remunerated activity/ies: GlaxoSmithKline; Non-remunerated activity/ies: H3 Biomedicine; Non-remunerated activity/ies: Innate Pharma; Non-remunerated activity/ies: Janssen-Cilag; Non-remunerated activity/ies: Kyowa Hakko Kirin; Non-remunerated activity/ies: Loxo; Non-remunerated activity/ies: Lytix Biopharma ; Non-remunerated activity/ies: MedImmune; Non-remunerated activity/ies: Menarini; Non-remunerated activity/ies: Merck Sharp & Dohme, Merrimack; Full / Part-time employment: Merus; Non-remunerated activity/ies: Millennium Pharmaceuticals; Non-remunerated activity/ies: Nanobiotix; Non-remunerated activity/ies: Nektar; Non-remunerated activity/ies: Novartis; Non-remunerated activity/ies: Octimet; Non-remunerated activity/ies: OncoEthix; Non-remunerated activity/ies: Onyx; Non-remunerated activity/ies: Orion Pharma GmbH; Non-remunerated activity/ies: Oryzon Genomics; Non-remunerated activity/ies: Pfizer; Non-remunerated activity/ies: Pierre Fabre; Non-remunerated activity/ies: Roche/Genentech; Non-remunerated activity/ies: Sanofi/Aventis; Non-remunerated activity/ies: Taiho Pharmaceutical; Non-remunerated activity/ies: Tesaro; Non-remunerated activity/ies: Xencor; Non-remunerated activity/ies: Roche. C. Le Tourneau: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (institution): Novartis; Advisory / Consultancy: Amgen; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Merck Serono; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD. V. Subbiah: Advisory / Consultancy: MedImmune; Research grant / Funding (institution), Travel / Accommodation / Expenses: PharmaMar; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): NanoCarrier; Research grant / Funding (institution): Northwest Biotherapeutics; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Berg; Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Fujifilm; Research grant / Funding (institution): D3 Oncology Solutions; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): MultiVir; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): Vegenics; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Alfasigma; Research grant / Funding (institution): Agensys; Research grant / Funding (institution): Idera; Research grant / Funding (institution): Boston Biomedical; Research grant / Funding (institution): InhibRx; Research grant / Funding (institution): Exelixis. S. Kao: Honoraria (self), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self): Roche; Research grant / Funding (institution): Merck Sharp & Dohme; Travel / Accommodation / Expenses: Boehringer Ingelheim. P. Cassier: Honoraria (self), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: SERVIER; Research grant / Funding (institution): Celgene ; Research grant / Funding (institution): Bristol-Myers Squibb ; Research grant / Funding (institution): Lilly . M. Khasraw: Honoraria (self): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Lilly; Research grant / Funding (institution): Specialised Therapeutics . H. Fang: Shareholder / Stockholder / Stock options, Full / Part-time employment: AbbVie. M. Patel: Shareholder / Stockholder / Stock options, Full / Part-time employment: AbbVie. W. Henner: Shareholder / Stockholder / Stock options, Full / Part-time employment: AbbVie. J. Hayflick: Shareholder / Stockholder / Stock options, Full / Part-time employment: AbbVie. M. McDevitt: Shareholder / Stockholder / Stock options, Full / Part-time employment: AbbVie. F. Barlesi: Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : AstraZeneca ; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : Bayer; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : Bristol-Myers Squibb; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : Boehringer Ingelheim; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : Eli Lilly Oncology; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : F. Hoffmann-La Roche Ltd; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : Novartis; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : Merck ; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : MSD; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : Pierre Fabre; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : Pfizer; Honoraria (self), Honoraria (institution), Personal/Institutional financial interests : Takeda; Honoraria (institution), Institutional financial interests : AbbVie; Honoraria (institution), Institutional financial interests : Amgen; Honoraria (institution), Institutional financial interests : ACEA; Honoraria (institution), Institutional financial interests : Eisai; Honoraria (institution), Institutional financial interests : Genentech; Honoraria (institution), Institutional financial interests : Ipsen; Honoraria (institution), Institutional financial interests : Ignyta; Honoraria (institution), Institutional financial interests : Innate Pharma; Honoraria (institution), Institutional financial interests : Loxo; Honoraria (institution), Institutional financial interests : MedImmune; Honoraria (institution), Institutional financial interests : Sanofi-Aventis. All other authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract